GlassScriptPhysician profile
Kevin L Pritchett
NPI 1174522197
$1,420.75
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,335 · 2020: $29.35 · 2021: $37.00 · 2022: $19.70.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $1,104.27 | 2019 | |
| Abbvie INC. | $56.70 | 2021-2022 | |
| Amarin Pharma, INC. | $46.96 | 2019 | |
| Novartis Pharmaceuticals Corporation | $36.83 | 2019 | |
| Sanofi Pasteur INC. | $36.23 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.78 | 2019 | |
| Lilly USA, LLC | $17.82 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.43 | 2020 | |
| Astellas Pharma US INC | $14.23 | 2019 | |
| Strongbridge US INC. | $13.92 | 2020 | |
| Amgen INC. | $12.66 | 2019 | |
| Circassia INC. | $12.53 | 2019 | |
| Merck Sharp & Dohme LLC | $12.37 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.02 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Pritchett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.